All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

OBX-115 Earns FDA Fast Track Designation for Advanced Melanoma

July 9th 2024

The FDA has granted fast track designation to OBX-115 for advanced melanoma that is refractory to or relapsed after immune checkpoint inhibitors.

Researchers Report First Effective Use of Immunotherapy for Most Common Subtype of Colorectal Cancer

July 9th 2024

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.

Myeloma Data Presented at ASCO Highlight Continued Evolution of Treatment Paradigm

July 9th 2024

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

Remestemcel-L BLA Is Resubmitted for Steroid-Refractory aGVHD

July 9th 2024

The BLA seeking approval for remestemcel-L for children with steroid-refractory acute graft-vs-host-disease has been resubmitted to the FDA.

NDA Resubmission Planned for Rivoceranib/Camrelizumab in Unresectable HCC Following FDA CRL

July 9th 2024

Elevar Therapeutics plans to resubmit a new drug application for rivoceranib plus camrelizumab for first-line unresectable hepatocellular carcinoma.

Hope: A Critical Concept in Oncology, but Open to Interpretation

July 9th 2024

Maurie Markman, MD, details the concept of hope during cancer diagnoses, touching on the announcement from Catherine, Princess of Wales.

Neoadjuvant Sacituzumab Govitecan Data Draw Curiosity in Cisplatin-Ineligible MIBC

July 9th 2024

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.

FDA Grants Fast Track Designation to BNT324/DB-1311 in mCRPC

July 8th 2024

The FDA has granted fast track designation to BNT324/DB-1311 for metastatic castration-resistant prostate cancer.

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 8th 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

New Study from Roswell Park Pinpoints Cells That May Drive Treatment Resistance in Prostate Cancer

July 8th 2024

Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.

Tazemetostat NDA Receives Priority Review in China for R/R Follicular Lymphoma

July 8th 2024

China’s NMPA has granted priority review to an NDA for tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma.

China’s NMPA Approves Selinexor for R/R DLBCL

July 8th 2024

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

ADI-270 Earns FDA Fast Track Designation for Pretreated Advanced ccRCC

July 8th 2024

The FDA has granted fast track designation to ADI-270 for advanced clear cell renal cell carcinoma after an immune checkpoint inhibitor and VEGF inhibitor.

European Commission Approves Osimertinib Plus Chemo for Advanced EGFR+ NSCLC

July 8th 2024

Frontline osimertinib plus chemotherapy has been approved in the European Union for adult patients with advanced EGFR-mutated non–small cell lung cancer.

Tiragolumab Plus Atezolizumab/Chemo Misses Survival End Points in Metastatic Nonsquamous NSCLC

July 8th 2024

First-line tiragolumab plus atezolizumab and chemotherapy failed to improve survival in advanced nonsquamous non–small cell lung cancer.

REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer

July 8th 2024

Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.

Lewis Katz School of Medicine at Temple University, Fox Chase Cancer Center Researcher Lucia Borriello Elected to Board of Directors of the Metastasis Research Society

July 7th 2024

Assistant professor Lucia Borriello, of Fox Chase Cancer Center, was recently elected to the Board of Directors for the Metastasis Research Society.

Investigating Risk-Based Treatment Strategies for Pediatric Non-Rhabdomyosarcoma Soft-Tissue Sarcoma

July 7th 2024

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

Dana-Farber Cancer Institute Partners With Massachusetts Firefighters to Address Cancer Risks

July 6th 2024

Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, addressing the heightened cancer risk faced by firefighters.

STAT3 Degrader KT-333 is Well Tolerated Across R/R Hematologic Malignancies and Solid Tumors

July 6th 2024

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.